stockportfolio.pro
ProKidney Corp. (PROK)
Healthcare · Biotechnology · NasdaqCM
ProKidney Corp. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $76,000 | $893,000 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-26.75M | $-55.15M | $-108.03M | $-35.47M | $-61.19M | $-68.99M |
| Net margin | — | — | — | — | -80507.9% | -7725.2% |
Source: ProKidney Corp. SEC filings (10-K).
Explore 6 years of ProKidney Corp. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PROK in your portfolio →
ProKidney Corp. financial history by metric
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp. — frequently asked questions
What is ProKidney Corp.'s revenue?
ProKidney Corp. (PROK) reported revenue of $893,000 for fiscal year 2025, up 1075.0% from the prior year, according to its SEC filings.
Is ProKidney Corp. profitable?
No — PROK reported a net loss of $-68.99M in fiscal 2025.
What is PROK's P/E ratio?
ProKidney Corp. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does ProKidney Corp. have?
As of fiscal year 2025, PROK carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is ProKidney Corp.'s market cap?
ProKidney Corp. (PROK) has a market capitalization of about $502.93M, based on the latest data in our nightly-refreshed cache.
When does ProKidney Corp.'s fiscal year end?
PROK's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from ProKidney Corp.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.